Concepts (211)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Squamous Cell | 10 | 2022 | 172 | 4.520 |
Why?
|
| Head and Neck Neoplasms | 13 | 2023 | 149 | 4.020 |
Why?
|
| Parotid Neoplasms | 3 | 2021 | 14 | 2.130 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 20 | 2.020 |
Why?
|
| Tongue Neoplasms | 3 | 2021 | 19 | 2.000 |
Why?
|
| Laryngeal Neoplasms | 5 | 2023 | 34 | 1.930 |
Why?
|
| Robotic Surgical Procedures | 3 | 2020 | 33 | 1.730 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 137 | 1.290 |
Why?
|
| Neck Dissection | 3 | 2021 | 20 | 1.240 |
Why?
|
| Retrospective Studies | 23 | 2023 | 3538 | 1.110 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 206 | 1.100 |
Why?
|
| Facial Nerve | 3 | 2021 | 13 | 1.060 |
Why?
|
| Parotid Gland | 3 | 2021 | 17 | 1.060 |
Why?
|
| Dissection | 3 | 2021 | 25 | 1.060 |
Why?
|
| Lymphatic Metastasis | 3 | 2021 | 93 | 1.010 |
Why?
|
| Salvage Therapy | 3 | 2023 | 35 | 0.960 |
Why?
|
| Papillomavirus Infections | 2 | 2022 | 20 | 0.900 |
Why?
|
| Postoperative Complications | 5 | 2020 | 916 | 0.890 |
Why?
|
| Drug Utilization | 2 | 2020 | 22 | 0.850 |
Why?
|
| Humans | 38 | 2023 | 27074 | 0.830 |
Why?
|
| Narcotics | 2 | 2020 | 38 | 0.820 |
Why?
|
| Analgesia | 2 | 2020 | 38 | 0.810 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 7 | 0.780 |
Why?
|
| Survival Rate | 8 | 2021 | 342 | 0.760 |
Why?
|
| Male | 25 | 2023 | 14772 | 0.730 |
Why?
|
| Gloves, Surgical | 1 | 2021 | 7 | 0.720 |
Why?
|
| Neoplasm Seeding | 1 | 2021 | 9 | 0.710 |
Why?
|
| Middle Aged | 20 | 2021 | 8923 | 0.710 |
Why?
|
| Surgical Instruments | 1 | 2021 | 25 | 0.710 |
Why?
|
| Adenolymphoma | 1 | 2020 | 4 | 0.710 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2020 | 6 | 0.710 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 29 | 0.700 |
Why?
|
| Glottis | 1 | 2020 | 4 | 0.700 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 24 | 0.700 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 51 | 0.690 |
Why?
|
| Prescriptions | 1 | 2020 | 16 | 0.690 |
Why?
|
| Aged | 19 | 2023 | 8997 | 0.680 |
Why?
|
| Chemoradiotherapy | 3 | 2023 | 61 | 0.660 |
Why?
|
| Pain, Postoperative | 2 | 2020 | 317 | 0.650 |
Why?
|
| Human papillomavirus 16 | 1 | 2019 | 6 | 0.640 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2019 | 4 | 0.640 |
Why?
|
| Female | 22 | 2021 | 15213 | 0.640 |
Why?
|
| Pharyngectomy | 1 | 2019 | 3 | 0.640 |
Why?
|
| Recovery of Function | 1 | 2020 | 295 | 0.630 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 62 | 0.620 |
Why?
|
| Sarcoma | 1 | 2021 | 147 | 0.590 |
Why?
|
| Databases, Factual | 4 | 2021 | 347 | 0.490 |
Why?
|
| Tonsillar Neoplasms | 1 | 2014 | 3 | 0.450 |
Why?
|
| Adult | 13 | 2020 | 7831 | 0.450 |
Why?
|
| Meningeal Neoplasms | 1 | 2014 | 14 | 0.440 |
Why?
|
| Dura Mater | 1 | 2014 | 16 | 0.440 |
Why?
|
| Laryngectomy | 4 | 2023 | 21 | 0.440 |
Why?
|
| Teratoma | 1 | 2012 | 4 | 0.410 |
Why?
|
| Surgical Flaps | 1 | 2012 | 49 | 0.390 |
Why?
|
| Laryngeal Edema | 1 | 2011 | 2 | 0.380 |
Why?
|
| Angioedema | 1 | 2011 | 2 | 0.380 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 18 | 0.380 |
Why?
|
| Airway Obstruction | 1 | 2011 | 20 | 0.380 |
Why?
|
| Laryngeal Diseases | 1 | 2011 | 3 | 0.370 |
Why?
|
| Ear Diseases | 1 | 2011 | 3 | 0.370 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 363 | 0.370 |
Why?
|
| Nose Diseases | 1 | 2011 | 6 | 0.370 |
Why?
|
| Gravitation | 1 | 2010 | 1 | 0.360 |
Why?
|
| Barotrauma | 1 | 2010 | 3 | 0.360 |
Why?
|
| Nose Neoplasms | 2 | 2022 | 40 | 0.360 |
Why?
|
| Accidents | 1 | 2010 | 2 | 0.360 |
Why?
|
| Tympanic Membrane | 1 | 2010 | 4 | 0.360 |
Why?
|
| Ear Canal | 1 | 2010 | 4 | 0.360 |
Why?
|
| Head Movements | 1 | 2010 | 6 | 0.360 |
Why?
|
| Leisure Activities | 1 | 2010 | 15 | 0.360 |
Why?
|
| Tongue | 2 | 2021 | 10 | 0.350 |
Why?
|
| Acceleration | 1 | 2010 | 21 | 0.350 |
Why?
|
| Hypersensitivity | 1 | 2011 | 47 | 0.350 |
Why?
|
| Edema | 1 | 2010 | 25 | 0.350 |
Why?
|
| Prognosis | 3 | 2019 | 785 | 0.340 |
Why?
|
| Chylothorax | 1 | 2010 | 1 | 0.340 |
Why?
|
| United States | 6 | 2021 | 2035 | 0.330 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 94 | 0.320 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 347 | 0.320 |
Why?
|
| Papillomaviridae | 2 | 2022 | 19 | 0.320 |
Why?
|
| Betacoronavirus | 2 | 2020 | 74 | 0.310 |
Why?
|
| Cohort Studies | 4 | 2020 | 1890 | 0.310 |
Why?
|
| Young Adult | 6 | 2020 | 1994 | 0.310 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 174 | 0.310 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 86 | 0.300 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 90 | 0.300 |
Why?
|
| Lens Cortex, Crystalline | 1 | 2007 | 3 | 0.290 |
Why?
|
| Lens Nucleus, Crystalline | 1 | 2007 | 6 | 0.290 |
Why?
|
| Lens, Crystalline | 1 | 2007 | 33 | 0.290 |
Why?
|
| Adolescent | 4 | 2020 | 2172 | 0.270 |
Why?
|
| Risk Assessment | 2 | 2019 | 624 | 0.270 |
Why?
|
| Treatment Outcome | 3 | 2020 | 3485 | 0.270 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2018 | 29 | 0.260 |
Why?
|
| Margins of Excision | 2 | 2021 | 32 | 0.220 |
Why?
|
| Neck | 2 | 2023 | 26 | 0.210 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2023 | 36 | 0.210 |
Why?
|
| Otolaryngology | 2 | 2020 | 29 | 0.210 |
Why?
|
| Pilot Projects | 2 | 2022 | 420 | 0.200 |
Why?
|
| Free Tissue Flaps | 2 | 2019 | 15 | 0.200 |
Why?
|
| SEER Program | 2 | 2019 | 42 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2020 | 4777 | 0.200 |
Why?
|
| Cell-Derived Microparticles | 1 | 2022 | 7 | 0.200 |
Why?
|
| Age Factors | 3 | 2019 | 766 | 0.190 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 300 | 0.190 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2022 | 65 | 0.190 |
Why?
|
| Prospective Studies | 2 | 2021 | 1778 | 0.190 |
Why?
|
| Length of Stay | 2 | 2023 | 313 | 0.180 |
Why?
|
| Chondrosarcoma | 1 | 2021 | 43 | 0.180 |
Why?
|
| Cytological Techniques | 1 | 2021 | 14 | 0.180 |
Why?
|
| Pain Measurement | 2 | 2020 | 483 | 0.180 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 8 | 0.170 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2020 | 11 | 0.170 |
Why?
|
| Urban Health Services | 1 | 2020 | 14 | 0.170 |
Why?
|
| Risk Factors | 3 | 2021 | 2302 | 0.170 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 29 | 0.170 |
Why?
|
| Point-of-Care Testing | 1 | 2020 | 29 | 0.170 |
Why?
|
| Paraganglioma | 1 | 2019 | 4 | 0.160 |
Why?
|
| Preoperative Care | 1 | 2020 | 117 | 0.160 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2019 | 23 | 0.160 |
Why?
|
| Frailty | 1 | 2019 | 34 | 0.160 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 9 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 102 | 0.160 |
Why?
|
| Head | 1 | 2019 | 23 | 0.160 |
Why?
|
| Medical Illustration | 1 | 2019 | 13 | 0.160 |
Why?
|
| Larynx | 1 | 2019 | 10 | 0.160 |
Why?
|
| Lymph Nodes | 1 | 2019 | 72 | 0.160 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 175 | 0.160 |
Why?
|
| Pharynx | 1 | 2019 | 12 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 44 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 44 | 0.150 |
Why?
|
| Reference Values | 1 | 2019 | 186 | 0.150 |
Why?
|
| Morphine | 1 | 2019 | 72 | 0.150 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2018 | 3 | 0.150 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 329 | 0.150 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 1792 | 0.150 |
Why?
|
| Telemedicine | 1 | 2020 | 97 | 0.150 |
Why?
|
| Aging | 1 | 2007 | 1544 | 0.150 |
Why?
|
| Carcinoma | 1 | 2018 | 67 | 0.150 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 482 | 0.140 |
Why?
|
| Invasive Fungal Infections | 1 | 2017 | 5 | 0.140 |
Why?
|
| Mucormycosis | 1 | 2017 | 8 | 0.140 |
Why?
|
| Aspergillosis | 1 | 2017 | 11 | 0.140 |
Why?
|
| Frozen Sections | 1 | 2017 | 14 | 0.140 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 229 | 0.130 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 20 | 0.130 |
Why?
|
| Markov Chains | 1 | 2015 | 33 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2015 | 49 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 123 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 107 | 0.120 |
Why?
|
| Rhinitis | 1 | 2017 | 144 | 0.120 |
Why?
|
| Sinusitis | 1 | 2017 | 162 | 0.110 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 99 | 0.110 |
Why?
|
| Neoplasm Proteins | 1 | 2014 | 56 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 366 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 348 | 0.100 |
Why?
|
| Drainage | 2 | 2010 | 39 | 0.100 |
Why?
|
| Cricoid Cartilage | 1 | 2012 | 1 | 0.100 |
Why?
|
| Forearm | 1 | 2012 | 19 | 0.100 |
Why?
|
| Mouth Floor | 1 | 2011 | 1 | 0.100 |
Why?
|
| Tongue Diseases | 1 | 2011 | 1 | 0.100 |
Why?
|
| Organ Transplantation | 1 | 2012 | 33 | 0.090 |
Why?
|
| Laryngoscopy | 1 | 2011 | 18 | 0.090 |
Why?
|
| Trachea | 1 | 2012 | 46 | 0.090 |
Why?
|
| Patient Admission | 1 | 2011 | 22 | 0.090 |
Why?
|
| Skin Neoplasms | 1 | 2012 | 80 | 0.090 |
Why?
|
| Otoscopy | 1 | 2010 | 1 | 0.090 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 8 | 0.090 |
Why?
|
| Hearing Tests | 1 | 2010 | 10 | 0.090 |
Why?
|
| Intubation, Intratracheal | 1 | 2011 | 94 | 0.090 |
Why?
|
| Mediastinal Diseases | 1 | 2010 | 4 | 0.080 |
Why?
|
| Hematoma | 1 | 2010 | 19 | 0.080 |
Why?
|
| Intensive Care Units | 1 | 2011 | 261 | 0.080 |
Why?
|
| Algorithms | 1 | 2011 | 350 | 0.080 |
Why?
|
| Recurrence | 1 | 2010 | 310 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 255 | 0.080 |
Why?
|
| Pandemics | 2 | 2020 | 237 | 0.070 |
Why?
|
| Hypertension | 1 | 2010 | 192 | 0.070 |
Why?
|
| Lasers | 1 | 2007 | 17 | 0.070 |
Why?
|
| Embryo, Mammalian | 1 | 2007 | 25 | 0.070 |
Why?
|
| Scattering, Radiation | 1 | 2007 | 33 | 0.070 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2007 | 75 | 0.070 |
Why?
|
| Fetus | 1 | 2007 | 38 | 0.070 |
Why?
|
| Rabbits | 1 | 2007 | 182 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2022 | 683 | 0.050 |
Why?
|
| Immobilization | 1 | 2023 | 13 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2023 | 9 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 51 | 0.050 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 36 | 0.050 |
Why?
|
| Biology | 1 | 2022 | 8 | 0.050 |
Why?
|
| Apoptosis | 1 | 2022 | 213 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 257 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 20 | 0.040 |
Why?
|
| Nasal Cavity | 1 | 2020 | 32 | 0.040 |
Why?
|
| Emergencies | 1 | 2020 | 32 | 0.040 |
Why?
|
| Genomics | 1 | 2020 | 64 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 68 | 0.040 |
Why?
|
| Animals | 1 | 2007 | 3642 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 302 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 167 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 464 | 0.040 |
Why?
|
| Mucor | 1 | 2017 | 5 | 0.030 |
Why?
|
| Aspergillus | 1 | 2017 | 7 | 0.030 |
Why?
|
| Nasal Surgical Procedures | 1 | 2017 | 10 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 949 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 46 | 0.030 |
Why?
|
| Nose | 1 | 2017 | 38 | 0.030 |
Why?
|
| Acute Disease | 1 | 2017 | 176 | 0.030 |
Why?
|
| Endoscopy | 1 | 2017 | 179 | 0.030 |
Why?
|
| Decision Making | 1 | 2017 | 223 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 158 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 189 | 0.030 |
Why?
|